Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, L. Calzetta, A. Segreti, F. Facciolo, P. Rogliani, M. G. Matera (Rome, Naples, Italy). Translational study searching for synergy between glycopyrronium and indacaterol. Eur Respir J 2014; 44: Suppl. 58, 1516

Member's Comments

No comment yet.

Related content which might interest you: Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Inhaler technique – A time to re-educate patients? Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Safety of tiotropium in renally impaired patients Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014